Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Niger J Clin Pract ; 24(6): 808-813, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34121726

ABSTRACT

BACKGROUND: Mean platelet volume (MPV) is associated with cardiovascular morbidity and mortality in type 2 diabetic patients. However, the effects of blood glucose regulation and treatment regime on MPV has not been adequately studied in type 2 diabetic patients. Aims: We studied the effects of blood glucose regulation and treatment regimen on mean platelet volume in Type 2 diabetic patients. SUBJECTS AND METHODS: A total of 232 diabetic patients who were admitted to the hospital in short intervals of 3 months in the last 2 years were included in the study. When the second admission HbA1c was greater than the first admission HbA1c, they were classified as being in the deteriorated blood glucose regulation group, otherwise they were classified in the improved blood glucose regulation group. Also, the deteriorated and improved blood glucose regulation groups were classified based on therapy modalities as the sulfonylurea + metformin group and the insulin + metformin group. Paired t-test was used for comparison of the groups. RESULTS: Of the 232 patients, 98 (42.2%) were male and 134 (57.8%) were female. There were 126 (55.2%) patients using sulfonylurea + metformin, while 106 (44.8%) patients were using insulin + metformin. MPV levels were significantly increased in patients with deteriorating glucose regulation (p = 0.003). This increase in MPV was only seen in the oral hypoglycemic treatment group (p = 0.003). CONCLUSIONS: Our results suggested a close relationship between poor glycemic control and increased platelet activity in type 2 diabetic patients with oral antidiabetic therapy when compared to the insulin and metformin therapy modality.


Subject(s)
Diabetes Mellitus, Type 2 , Metformin , Blood Glucose , Diabetes Mellitus, Type 2/drug therapy , Female , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents/therapeutic use , Male , Mean Platelet Volume , Metformin/therapeutic use
2.
Niger J Clin Pract ; 22(9): 1224-1228, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31489858

ABSTRACT

OBJECTIVE: To study the relationship between vitamin D and thyroid antibodies with thyroid benign-malign neoplasms. MATERIALS AND METHODS: The vitamin D vitamin and thyroid antibodies of 179 patients who underwent thyroidectomy for thyroid nodule were retrospectively reviewed. RESULTS: The mean age of the patients was 44.97 ± 14.139. Vitamin D levels were 14.473 ± 4.9999 ng/ml in women and 19.584 ± 6.1981 ng/ml in men and the mean was 15.016 ± 5.3579 ng/ml. There was a significant relationship between sex and vitamin D level (P < 0, 05). Antithyroglobulin antibody (anti-TGB) had been detected in 95 patients and Antithyroid peroxidase antibody (anti TPO) in 58 patients. There was no significant relationship between vitamin D levels (P: 0, 65), anti-TPO positivity (P: 0, 86), and anti-TGB (P: 0, 12) with benign-malignant neoplasm of thyroid. There was no relationship between vitamin D and metastatic disease (P: 0, 30) as well. In addition, no association was found between malignancy and metastasis (P = 0.068, P = 0.14, P: 0, P = 0, respectively) with thyroid antibody positivity (anti TPO and/or anti TGB) in severe deficiency (<10 ng/ml) and deficiency (<20 ng/ml) of vitamin D. CONCLUSION: Vitamin D deficiency or thyroid autoantibodies did not have any significant effect on thyroid malignancies or metastatic disease separately or together.


Subject(s)
Adenoma, Oxyphilic/blood , Autoantibodies/blood , Cholecalciferol/blood , Thyroid Neoplasms/blood , Vitamin D Deficiency/complications , Adenoma, Oxyphilic/surgery , Adult , Age Distribution , Female , Humans , Male , Middle Aged , Retrospective Studies , Sex Distribution , Thyroid Neoplasms/surgery , Thyroidectomy , Vitamin D/blood , Vitamin D Deficiency/blood
3.
J Endocrinol Invest ; 39(2): 185-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26142741

ABSTRACT

PURPOSE: Chemokines play an important role in the pathogenesis of autoimmune thyroid diseases. Platelet factor 4 (PF4, CXCL4) released from activated platelets is a chemokine. However, its clinical importance in autoimmune thyroiditis remains unknown. This study is intended to determine circulating levels of PF4 levels in patients with autoimmune thyroiditis (AIT). METHODS: Circulating levels of PF4 were measured in 34 consecutive patients with newly diagnosed AIT and 18 euthyroid controls. Among AIT group, 16 patients were euthyroid and 18 had subclinic hypothyroidism. Controls and individuals with AIT were similar in terms of age. RESULTS: Serum levels of PF4 were comparable in patients with AIT and in controls. Among patients with AIT, PF4 was significantly lower in those with subclinical hypothyroidism than in euthyroid individuals (p = 0.001). In correlation analysis, PF4 was negatively correlated with TSH (r = -0.663, p = 0.000) and positively correlated with free T4 (r = 0.428, p = 0.012). There was not any significant correlation between PF4 and AbTPO, AbTg. CONCLUSION: The present study demonstrated for the first time that circulating PF4 levels are decreased in subclinically hypothyroid AIT. This result draws attention to the circulating PF4 levels in subclinically hypothyroid AIT and may shed light on further researches at this topic.


Subject(s)
Asymptomatic Diseases , Down-Regulation , Hashimoto Disease/blood , Platelet Factor 4/blood , Thyroiditis, Autoimmune/blood , Adolescent , Adult , Aged , Autoantibodies/analysis , Autoantigens , Biomarkers/blood , Female , Hashimoto Disease/immunology , Hashimoto Disease/physiopathology , Humans , Iodide Peroxidase/antagonists & inhibitors , Iron-Binding Proteins/antagonists & inhibitors , Middle Aged , Severity of Illness Index , Thyroiditis, Autoimmune/immunology , Thyroiditis, Autoimmune/physiopathology , Thyrotropin/blood , Thyroxine/blood , Young Adult
4.
Hum Exp Toxicol ; 35(6): 608-12, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26224042

ABSTRACT

INTRODUCTION: Cardiovascular, respiratory, and cerebrovascular diseases and malignancies are responsible for morbidity and mortality in acromegaly. Also these diseases are associated with chronic inflammation. The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are currently gaining interest as new markers of inflammation. Moreover, increased morbidity and mortality are positively correlated with the presence of diabetes and levels of insulin-like growth factor 1 (IGF-1) in acromegaly. The objective of the present study was to investigate the relationship between these markers and acromegaly according to plasma glucose status and serum IGF-1 levels. MATERIALS AND METHODS: We retrospectively analyzed data from 61 acromegaly patients who were in a newly diagnosed period (35 male, 26 female; mean age 38.13 ± 13.98). Patients with normal plasma glucose (n = 27), impaired fasting glucose (n = 18), and diabetes mellitus (n = 16) were categorized into three different groups. NLR and PLR were compared between the study groups and were evaluated according to IGF-1 levels. RESULTS: There were no statistically significant differences in NLR and PLR measurements among the study groups (p > 0.05). However, there were significant positive correlations between NLR and IGF-1 levels and between PLR and IGF-1 levels when all patients were evaluated (r = 0.334, p = 0.011 and r = 0.277, p = 0.035, respectively). CONCLUSIONS: This is the first report studying the relationship of NLR and PLR with glucose status and IGF-1 levels in acromegaly patients. Our study results suggest that subclinical inflammation may play a role in increased incidence of mortality and morbidity, which depends on uncontrolled IGF-1 levels in patients with acromegaly.


Subject(s)
Acromegaly/blood , Blood Glucose/analysis , Blood Platelets/cytology , Insulin-Like Growth Factor I/analysis , Lymphocytes/cytology , Neutrophils/cytology , Acromegaly/immunology , Adolescent , Adult , Aged , Biomarkers/blood , Blood Cell Count , Blood Platelets/immunology , Female , Humans , Inflammation/blood , Lymphocytes/immunology , Male , Middle Aged , Neutrophils/immunology , Retrospective Studies , Young Adult
5.
Minerva Endocrinol ; 40(1): 15-22, 2015 Mar.
Article in English | MEDLINE | ID: mdl-24699706

ABSTRACT

AIM: The literature is inconclusive concerning the prognostic factors and therapeutic management of papillary thyroid microcarcinoma (PTMC). Herein we report on our extensive experience with PTMC in relation to clinicopathological characteristics and prognostic factors. METHODS: In all, 248 patients that were diagnosed and treated for PTMC between 2007 and 2012 were retrospectively analyzed. Demographic and tumor characteristics at presentation, and recurrence during follow-up were noted. RESULTS: Total thyroidectomy and radioactive iodine (RAI) ablation treatment were performed in all patients. Bilateral involvement, vascular and capsular invasion, extra-thyroidal extension, and lymph node metastasis occurred significantly more frequently in patients with tumor size>5 mm (P<0.05). Multivariate statistical analysis showed that a clinically suspected diagnosis (OR:0.095; P=0.043) and elevated thyroglobulin (TG) level (OR: 1.083; P=0.011; cut-off value≥7.98 ngmL(-1)) were significant and independent risk factors for lymph node metastasis, with a sensitivity of 57% and specificity of 83%. After a median follow-up of 2 years (range:0.3-11 years), 10 (4%) of the 248 patients had recurrent disease. According to multivariate analysis, lymph node metastasis (OR: 51.4; P=0.003) was the only independent predictor of recurrence. CONCLUSION: Our findings revealed that serum TG level and a clinically suspected diagnosis were risk factors for lymph node metastasis, while nodal metastasis was a predictor of recurrence.


Subject(s)
Carcinoma, Papillary/secondary , Lymphatic Metastasis , Thyroid Neoplasms/pathology , Adult , Aged , Biomarkers, Tumor/blood , Carcinoma, Papillary/pathology , Carcinoma, Papillary/radiotherapy , Carcinoma, Papillary/surgery , Female , Follow-Up Studies , Humans , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Metastasis , Prognosis , Recurrence , Retrospective Studies , Risk Factors , Sensitivity and Specificity , Thyroglobulin/blood , Thyroid Neoplasms/surgery , Tumor Burden , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...